SYS-CON MEDIA Authors: Elizabeth White, Peter Silva, Liz McMillan, Yeshim Deniz, Pat Romanski

News Feed Item

Eisai to Collaborate with Liverpool School of Tropical Medicine and University of Liverpool to Discover New Drugs Against Filariasis

HATFIELD, England, March 20, 2014 /PRNewswire/ --



Joint research project awarded a Global Health Innovative Technology Fund grant

Eisai announced today that it has entered a collaboration with the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool (UoL) to identify new drugs that are effective against lymphatic filariasis and onchocerciasis (river blindness), both major types of the parasitic tropical disease filariasis.  

Under the collaboration, Eisai will work with the nonprofit LSTM to develop and implement new tools and technologies for the control and treatment of tropical diseases, and with UoL, a world-class institute that has made major contributions toward understanding the mechanisms of drug action of several classes of anti-parasitic drugs, to identify and develop novel drug candidates that efficiently eliminate the bacteria Wolbachia.  Wolbachia live inside the parasitic worms, known as filariae, which cause lymphatic filariasis and onchocerciasis. These two filarial infectious diseases affect more than 150 million people worldwide.[1] As filariae are dependent on Wolbachia bacteria for growth, development, reproduction and survival, the worms can be effectively eradicated by first eliminating the Wolbachia inside them.

While current anti-filarial treatments are effective against larvae and microfilariae, they require many years of consistent, annual mass drug administration in endemic communities to successfully eliminate the adult worms. Anti-Wolbachia therapy is expected to lead to worm sterility and effective worm eradication, thereby reducing treatment times and improving therapeutic outcomes compared to existing anti-filarial drugs. Furthermore, as anti-Wolbachia programmes are still in their infancy, this collaboration has the potential to provide a unique opportunity to make a significant contribution to communities affected by filariasis.

To date, the screening of more than 10,000 potential anti-Wolbachia compounds has revealed approximately 50 potentially promising compounds, leading to identification of about six chemotypes with anti-infective potential. Eisai and its collaboration partners will focus on two of these with the aim of identifying a single candidate for potential drug development within one to two years.

This unique approach has been awarded a two-year grant by the Global Health Innovative Technology Fund (GHIT Fund), an international non-profit organisation that aims to promote the discovery of new health technologies for eliminating infectious diseases prevalent in developing countries.

In support of the World Health Organisation (WHO)'s programme to eliminate lymphatic filariasis by 2020, Eisai is supplying diethylcarbamazine (DEC) free of charge to the WHO. Under its collaboration with LSTM and UoL, Eisai aims to make new treatments available as early as possible to help patients with filariasis and thereby increase further the healthcare benefits provided to these patients and their families in developing and emerging countries.

Notes  to  editors

About  Anti-Wolbachia  Therapy 

Anti-Wolbachia therapy is a new method of treatment that eradicates the adult worms that can cause filariasis by eliminating bacteria known as Wolbachia that live in the cells of their bodies. This approach has the potential to significantly reduce the timescale of elimination programs, to provide alternatives to existing treatments, and to deliver tools that can be used in areas where current approaches are failing or cannot be deployed. Doxycycline, an antibiotic, is believed to work in this way and proof of concept has already been established in human field trials, which showed excellent results although requiring four to six weeks of daily treatment and being unsuitable for administration to children and pregnant women.

Under its collaboration with the Liverpool School of Tropical Medicine (LSTM) and University of Liverpool (UoL), Eisai will aim to identify potential new drug compounds that act more quickly and more effectively than doxycycline and that could be used across all population groups, and to develop these molecules to the stage of pre-clinical safety testing.

About Liverpool School of Tropical Medicine and the University of Liverpool

The LSTM is a non-profit charitable institution with a mission to develop and implement new tools and technologies for the control and treatment of tropical diseases. LSTM has an existing anti-Wolbachia program funded by the Bill and Melinda Gates Foundation and has developed assays and models to test compounds for anti-Wolbachia activity on a large scale.

The Department of Chemistry at the UoL has made major contributions toward understanding the mechanisms of drug action of several classes of anti-parasitic drugs. Over their 20 years in partnership, UoL and LSTM have adopted a "molecule to man" strategy to instigating its research projects, operating at all stages of the drug discovery pipeline up to and including clinical trials in humans. To date, a total of three projects have contributed to the portfolio of the Medicines for Malaria Venture (MMV), an organization that has developed the largest portfolio of anti-malarial drugs in history.

About  the  Global  Health  Innovative  Technology  Fund 

The Global Health Innovative Technology Fund (GHIT Fund) is an international non-profit organization aimed at advancing the research and development of new health technologies from Japan to fight infectious diseases prevalent specifically in the developing world, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases (NTDs). Established as a public-private partnership between the Government of Japan, a consortium of pharmaceutical companies, and the Bill & Melinda Gates Foundation, the GHIT Fund facilitates and funds research and development of new health technologies through partnership creation and grant-making activities. For further information, please visit: http://www.ghitfund.org.

About  Eisai 

Eisai is one of the world's leading research and development (R&D) based pharmaceutical companies and we define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).

Eisai concentrates its R&D activities in three key areas:

  • Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
  • Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies, etc.
  • Vascular/Immunological reaction including: thrombocytopenia, rheumatoid arthritis, psoriasis, inflammatory bowel disease

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 10,000 people worldwide. From its EMEA Knowledge Centre in Hatfield, UK, Eisai has recently expanded its business operations to include Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium, Russia and the Middle East.

For further information please visit our web site http://www.eisai.co.uk

References 

1.  Filaria-EU  2014  http://www.filaria.eu/fil/fil.html   


Date of preparation: March 2014
Job code: corporate-UK2026


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
This talk focuses on the application of DevOps fundamentals to include network infrastructure. It draws from real deployment case studies on the extension of today's paradigms to address the challenges of the network infrastructures' ability to seamlessly and cohesively integrate into agile workflows. In this session at DevOps Summit, Arista Networks will focus on configuration management using automation with a nod to future work necessary to include telemetry and ephemeral state information....
Avnet, Inc. has announced that it ranked No. 4 on the InformationWeek Elite 100 – a list of the top business technology innovators in the U.S. Avnet was recognized for the development of an innovative cloud-based training system that serves as the foundation for Avnet Academy – the company’s education and training organization focused on technical training around top IT vendor technologies. The development of this system allowed Avnet to quickly expand its IT-related training capabilities around...
SYS-CON Events announced today that dcVAST, a leader in IT infrastructure management, support service and cloud service, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. dcVAST provides cutting-edge IT services and IT infrastructure management services. dcVAST builds robust systems that are simple, secure and serviceable. dcVAST’s IT infrastructure support and IT services expertise can help companies r...
DevOps Summit, taking place Nov 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 17th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developmen...
While Docker continues to be the darling of startups, enterprises and IT innovators around the world, networking continues to be a real mess. Indeed, managing the interaction between Docker containers and networks has always been fraught with complications. Without automation in networking, the vision of running Docker at scale and letting IT run the same apps unchanged on the laptop and in the data center or for any cloud cannot be realized.
SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Isomorphic Software is the global leader in high-end, web-based business applications. We develop, market, and support the SmartClient & Smart GWT HTML5/Ajax platform, combining the productivity and performance of traditional desktop software ...
Artifactory binary repository management system. As one of the most widely used binary repositories and the only repository that offers a high availability clustered solution, the integration with Artifactory helps customers easily adopt CA Release Automation to optimize their entire software development lifecycle. “Artifactory is a standard maker at the continuous-integration domain and provides the user a powerful repository experience with the freedom to choose his own tools set and ecosyste...
The OnPage SOAP API provides programmatic access to OnPage messaging services. Typical applications include sending messages to individual OnPage users or groups and receiving tracking information for messages such as delivery and read timestamps or reply information. The API is based on open standards known collectively as "Web Services," which includes the Simple Object Access Protocol (SOAP), Web Services Definition Language (WSDL), and the XML Schema Definition language (XSD).
SYS-CON Events announced today the DevOps Foundation Certification Course, being held June ?, 2015, in conjunction with DevOps Summit and 16th Cloud Expo at the Javits Center in New York City, NY. This sixteen (16) hour course provides an introduction to DevOps – the cultural and professional movement that stresses communication, collaboration, integration and automation in order to improve the flow of work between software developers and IT operations professionals. Improved workflows will res...
Docker is becoming very popular--we are seeing every major private and public cloud vendor racing to adopt it. It promises portability and interoperability, and is quickly becoming the currency of the Cloud. In his session at DevOps Summit, Bart Copeland, CEO of ActiveState, discussed why Docker is so important to the future of the cloud, but will also take a step back and show that Docker is actually only one piece of the puzzle. Copeland will outline the bigger picture of where Docker fits a...
A new definition of Big Data & the practical applications of the defined components & associated technical architecture models This presentation introduces a new definition of Big Data, along with the practical applications of the defined components and associated technical architecture models. In his session at Big Data Expo, Tony Shan will start with looking into the concept of Big Data and tracing back the first definition by Doug Laney, and then he will dive deep into the description of 3V...
Ayla Networks, whose agile Internet of Things (IoT) platform makes it easy for manufacturers to deliver secure, connected products, today announced it has been included in the list of "Cool Vendors" in the Internet of Things report by Gartner, Inc. “Gartner knows how important it is that manufacturers of all kinds of products have the right IoT solution to help turn their products into connected ‘things,’” said David Friedman, CEO and co-founder of Ayla Networks. “The market for Ayla’s IoT pla...
SYS-CON Events announced today that CenturyLink, Inc., a leader in the network services market, has been named “Platinum Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. CenturyLink is the third largest telecommunications company in the United States and is recognized as a leader in the network services market by technology industry analyst firms. The company is a global leader in cloud infrastructure and ...
ScriptRock has been included in the list of "Cool Vendors" in the "Cool Vendors in DevOps 2015" report by Gartner, Inc.* ScriptRock provides visibility into the configuration state of an organization's IT environments, enabling the continuous delivery of mission critical services. For enterprises where downtime is not an option, ScriptRock's system-wide overwatch offers the assurance that misconfigurations and anomalies are caught before they affect the business. By satisfying this fundamental ...
As cloud gives an opportunity to businesses to buy services externally – how is cloud impacting your customers? In his General Session at 15th Cloud Expo, Fabio Gori, Director of Worldwide Cloud Marketing at Cisco, provided answers to big questions: Do you see hybrid cloud as where the world is going? What benefits does it bring? And how does Cisco connect all of these clouds? He also discussed Intercloud and Cisco’s investment on it.